Skip to Content

Idarucizumab Side Effects

For the Consumer

Applies to idarucizumab: intravenous solution

Along with its needed effects, idarucizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking idarucizumab:

Incidence Not Known

  • Anxiety
  • blurred vision
  • bone pain
  • chills
  • cold sweats
  • coma
  • confusion
  • convulsions
  • cool, pale skin
  • cough
  • dark-colored urine
  • deep or fast breathing with dizziness
  • depression
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • drowsiness
  • fast heartbeat
  • fever
  • general feeling of tiredness or weakness
  • headache
  • hives, itching, or skin rash
  • increased hunger
  • light-colored stools
  • loss of appetite
  • muscle tremors
  • nausea
  • nervousness
  • nightmares
  • numbness of the feet, hands, and around the mouth
  • pain in the chest, groin, or legs, especially the calves
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rapid, deep breathing
  • restlessness
  • seizures
  • severe, sudden headache
  • shakiness
  • slurred speech
  • stomach cramps
  • stomach pain, continuing
  • sudden loss of coordination
  • sudden, severe weakness or numbness in the arm or leg
  • sudden, unexplained shortness of breath
  • tightness in the chest
  • unusual tiredness or weakness
  • vision changes
  • vomiting
  • yellow eyes or skin

For Healthcare Professionals

Applies to idarucizumab: intravenous solution

General

The most common adverse reactions were hypokalemia, delirium, constipation, pyrexia, pneumonia, and headache.[Ref]

Cardiovascular

Common (1% to 10%): Thrombotic events[Ref]

Metabolic

Common (1% to 10%): Hypokalemia[Ref]

Psychiatric

Common (1% to 10%): Delirium[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, nausea[Ref]

Other

Common (1% to 10%): Pyrexia[Ref]

Respiratory

Common (1% to 10%): Pneumonia

Frequency not reported: Bronchospasm, hyperventilation[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]

Dermatologic

Frequency not reported: Rash, pruritus[Ref]

Immunologic

Frequency not reported: Hypersensitivity reactions[Ref]

References

1. "Product Information. Praxbind (idaruCIZUMAB)." Boehringer Ingelheim, Ridgefield, CT.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide